ArticleCirculation2014
Growth properties of cardiac stem cells are a novel biomarker of patients' outcome after coronary bypass surgery.
Article in Circulation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- The Biological Mechanisms of Action of Cardiac Progenitor Cell Therapy.Current cardiology reports · 2018Review
- Short Telomeres Induce p53 and Autophagy and Modulate Age-Associated Changes in Cardiac Progenitor Cell Fate.Stem cells (Dayton, Ohio) · 2018Article
- p53 Modulates the Fate of Cardiac Progenitor Cells Ex Vivo and in the Diabetic Heart In Vivo.EBioMedicine · 2017Article
- Combined Analysis of Endothelial, Hematopoietic, and Mesenchymal Stem Cell Compartments Shows Simultaneous but Independent Effects of Age and Heart Disease.Stem cells international · 2017Article
- Β-blockers treatment of cardiac surgery patients enhances isolation and improves phenotype of cardiosphere-derived cells.Scientific reports · 2016Article
- Oxytocin and cardioprotection in diabetes and obesity.BMC endocrine disorders · 2016Review
- Dual effects of VEGF-B on activating cardiomyocytes and cardiac stem cells to protect the heart against short- and long-term ischemia-reperfusion injury.Journal of translational medicine · 2016Article
- Stem cell therapy for CHD: towards translation.Cardiology in the young · 2015Review
- Pediatric End-Stage Failing Hearts Demonstrate Increased Cardiac Stem Cells.The Annals of thoracic surgery · 2015Article
- Cardiac aging - Getting to the stem of the problem.Journal of molecular and cellular cardiology · 2015Review
- Notch activation enhances lineage commitment and protective signaling in cardiac progenitor cells.Basic research in cardiology · 2015Article
- Revascularization of chronic hibernating myocardium stimulates myocyte proliferation and partially reverses chronic adaptations to ischemia.Journal of the American College of Cardiology · 2015Article
- Magnetic resonance imaging and multi-detector computed tomography assessment of extracellular compartment in ischemic and non-ischemic myocardial pathologies.World journal of cardiology · 2014Review
- Making it stick: chasing the optimal stem cells for cardiac regeneration.Expert review of cardiovascular therapy · 2014Review
- Predicting the future with stem cells.Circulation · 2014Article
- A Novel Class of Human Cardiac Stem Cells.Cardiology in reviewArticle
Corrections and comments
- Retraction · 2018-12-12Concerns/Issues about Data · Investigation by Company/Institution · Misconduct - Official Investigation(s) and/or Finding(s) · Upgrade/Update of Prior Notice(s) ·
- Expression of concern · 2018-11-20Concerns/Issues about Data · Investigation by Company/Institution · Misconduct - Official Investigation(s) and/or Finding(s) · Updated to Retraction · Upgrade/Update of Prior Notice(s) ·
- Correction · 2014-08-12Error in Image · Investigation by Journal/Publisher ·
- Correction · 2015-12-01Conflict of Interest ·
- Commented on by
- Commented on by
- Commented on by
- Erratum issuedCorrection.2015
- Erratum issued
- Expression of concern
- Expression of concern
- Retracted
Authors and funding
22 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundThe efficacy of bypass surgery in patients with ischemic cardiomyopathy is not easily predictable; preoperative clinical conditions may be similar, but the outcome may differ significantly. We hypothesized that the growth reserve of cardiac stem cells (CSCs) and circulating cytokines promoting CSC activation are critical determinants of ventricular remodeling in this patient population. METHODS AND
resultsTo document the growth kinetics of CSCs, population-doubling time, telomere length, telomerase activity, and insulin-like growth factor-1 receptor expression were measured in CSCs isolated from 38 patients undergoing bypass surgery. Additionally, the blood levels of insulin-like growth factor-1, hepatocyte growth factor, and vascular endothelial growth factor were evaluated. The variables of CSC growth were expressed as a function of the changes in wall thickness, chamber diameter and volume, ventricular mass-to-chamber volume ratio, and ejection fraction, before and 12 months after surgery. A high correlation was found between indices of CSC function and cardiac anatomy. Negative ventricular remodeling was not observed if CSCs retained a significant growth reserve. The high concentration of insulin-like growth factor-1 systemically pointed to the insulin-like growth factor-1-insulin-like growth factor-1 receptor system as a major player in the adaptive response of the myocardium. hepatocyte growth factor, a mediator of CSC migration, was also high in these patients preoperatively, as was vascular endothelial growth factor, possibly reflecting the vascular growth needed before bypass surgery. Conversely, a decline in CSC growth was coupled with wall thinning, chamber dilation, and depressed ejection fraction.
conclusionsThe telomere-telomerase axis, population-doubling time, and insulin-like growth factor-1 receptor expression in CSCs, together with a high circulating level of insulin-like growth factor-1, represent a novel biomarker able to predict the evolution of ischemic cardiomyopathy following revascularization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.